Madrigal Pharmaceuticals beat Q1 sales estimates with Rezdiffra, and catalysts like EU approval and pipeline plans add upside ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...

Madrigal Pharmaceuticals MDGL reported first-quarter 2025 loss of $3.32 per share, narrower than the Zacks Consensus Estimate of a loss of $3.62. In the year-ago quarter, the company had incurred a ...

Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...

We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Madrigal Pharmaceuticals has a 12-month low of $189.00 and a 12-month high of $377.46. Madrigal Pharmaceuticals ( NASDAQ:MDGL – Get Free Report ) last released its quarterly earnings data on ...

May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...